Targeting a good protein gone wild in Alzheimer’s and other diseases, Therini Bio raises $36M

The startup's CEO says a monoclonal antibody drug that selectively targets the protein could be used in parallel with recently approved drugs that look to clear amyloid beta out of the brains of Alzheimer's patients.